Clinical vaccine development for H5N1 influenza (Q30222083)

10 June 2017

Clinical vaccine development for H5N1 influenza (English)

1 reference

10 June 2017

Christopher H Clegg

1

1 reference

PubMed ID

23885822

10 June 2017

Joseph A Rininger

series ordinal

2

1 reference

PubMed ID

23885822

10 June 2017

Susan L Baldwin

series ordinal

3

1 reference

10 June 2017

1 July 2013

1 reference

Expert Review of Vaccines

10 June 2017

1 reference

10 June 2017

12

1 reference

10 June 2017

7

1 reference

10 June 2017

767-777

1 reference

Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985.

10 June 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

H5N1 vaccines: how prepared are we for a pandemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Preparing for a possible pandemic: influenza A/H5N1 vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Avian and pandemic influenza: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Airborne transmission of influenza A/H5N1 virus between ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

B cells and aging: molecules and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Towards an understanding of the adjuvant action of aluminium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

A comparative study of stress-mediated immunological functions with the adjuvanticity of alum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

The inflammasomes: guardians of the body

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

The mechanism of action of MF59 - an innately attractive adjuvant formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Influenza vaccine immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Hallmarks of CD4 T cell immunity against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

New horizons in adjuvants for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Use of defined TLR ligands as adjuvants within human vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Analysis of a monophosphoryl lipid A immunostimulant preparation from Salmonella minnesota R595 by high-performance liquid chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Adjuvant solution for pandemic influenza vaccine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Assessing the safety of adjuvanted vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Overview of global regulatory toxicology requirements for vaccines and adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Vaccination, squalene and anti-squalene antibodies: facts or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Association between H1N1 vaccination and narcolepsy-cataplexy: flu to sleep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811178

A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6101019

Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6101019

Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6101019

AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6101019

Strategies for broad global access to pandemic influenza vaccines.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6101019

Protein expression in the baculovirus system

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6101019

Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6101019

10.1586/14760584.2013.811178

26 November 2018

Identifiers

DOI

1 reference

10 June 2017

0 references

1 reference

PubMed ID

23885822